Effect of bFGF on HLA-DR expression of human bone marrow-derived mesenchymal stem cells.
There has been a steady rise in the therapeutic applications of bone marrow mesenchymal stem cells (BM-MSCs) because of their unique properties of multilineage differentiation and immune modulation as well as the ease in isolation. However, up-regulation of surface HLA-DR levels when maintaining MSCs in culture under the influence of mitotic factors such as Basic fibroblast growth factor (bFGF) is an area of concern when considering them for the purpose of clinical applications. Thus, we investigated the association of bFGF supplemented to the culture media and the surface expression levels of HLA-DR in BM-MSCs in order to optimize the yield, while keeping HLA-DR levels under permissible levels. Human BM-MSCs were culture expanded in the absence of bFGF and in the presence of 1 ng/ml or 2 ng/ml bFGF. The HLA-DR profile of the cultures was analyzed at the end of each passage. On comparing the percent HLA-DR+ cell population at different concentrations as well as absence of bFGF, significant differences were not observed in the HLA-DR expression levels of the MSC cultures which had reached complete confluence. However, variations in HLA-DR expressions levels were seen which could be traced to the age of cells in culture with values drastically reduced to below 4% on maintaining MSCs typically two to three days beyond achieving full confluence. On the basis of the findings from this study, no significant correlation could be established on the effect of bFGF in modulating HLA-DR surface expression of BM-MSCs. Instead, the data are suggestive of the reasoning that the duration for which BM-MSCs are maintained in culture directly influences their phenotypic characteristics in terms of HLA-DR expression levels, with lowest levels achieved on their prolonged maintenance in culture.
Stempeutics Research, Shirdi Sai Baba Cancer Hospital, Manipal, India.
Pratiksha A
PA
Dighe
Stempeutics Research, Shirdi Sai Baba Cancer Hospital, Manipal, India.
Pachaiyappan
P
Viswanathan
Stempeutics Research, Shirdi Sai Baba Cancer Hospital, Manipal, India.
Ashwin K
AK
Mruthunjaya
Stempeutics Research, Shirdi Sai Baba Cancer Hospital, Manipal, India.
Raviraja N
RN
Seetharam
D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D015870:Gene Expression; D006684:HLA-DR Antigens / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism*; D013997:Time Factors
D006684:HLA-DR Antigens; D016222:Fibroblast Growth Factor 2